Drug Trial Radar · NCT05208944
THIO Sequenced With Cemiplimab in Advanced NSCLC
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
227
Planned (sponsor's estimate)
Start
Jun 8, 2022
Primary completion
Sep 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Maia BiotechnologyIndustry
- Sponsor type
- Industry
- First posted
- Jan 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
THIO is a first-in-class small molecule telomere targeting agent, in development for the treatment of non-small cell lung cancer (NSCLC) in combination with cemiplimab (LIBTAYO®). THIO is preferentially incorporated into telomeres sequence in telomerase-positive cells leading to rapid telomere uncapping, genomic instability, and cell death. Cemiplimab is a programmed cell death protein 1 (PD-1) inhibitor recently approved as a first-line treatment for patients with locally advanced or metastatic NSCLC with 50% or more PD-L1 expression. It is hypothesized that THIO administration prior to cemiplimab would restore tumor responses to immunotherapy in subjects who either developed resistance or relapsed after receiving first line treatment with an immune check point inhibitor.
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
6-Thio-2'-DeoxyguanosineDrug
small molecule telomere targeting agent
CemiplimabDrug
programmed cell death protein 1 (PD-1) inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the safety and tolerability of THIO administered in sequence with cemiplimab in subjects with advanced NSCLCTime frame: Up to 2 years
- To assess the efficacy of THIO administered in sequence with cemiplimab in subjects with advanced NSCLCTime frame: Up to 2 years
- To assess the efficacy of THIO administered in sequence with cemiplimab in subjects with advanced NSCLCTime frame: Up to 2 years
- To determine the safety and tolerability of THIO administered in sequence with cemiplimab in subjects with advanced NSCLCTime frame: Up to 2 years
- To determine the safety and tolerability of THIO administered in sequence with cemiplimab in subjects with advanced NSCLCTime frame: Up to 2 years
Locations
40 sites in 8 countries. Site status is shown where the registry gives one.
Central Alabama Research
Birmingham, Alabama
Summit Health
Florham Park, New Jersey
Sunshine Coast Haematology and Oncology Clinic
Buderim, Queensland, Australia
Cancer Research SA
Adelaide, South Australia, Australia
St. Vincent Hospital Melbourne
Fitzroy, Victoria, Australia
MHAT "HEART AND BRAIN" EAD Clinic of Medical Oncology
Pleven, Bulgaria
MC Synexus Sofia EOOD
Sofia, Bulgaria
MHAT "Serdika" EOOD
Sofia, Bulgaria
UMHAT "Sofiamed"
Sofia, Bulgaria
LTD High Technology Hospital Medcenter
Batumi, Georgia
Israel-Georgian Medical Research Clinic Healthycore LTD
Tbilisi, Georgia
LTD "New Hospitals"
Tbilisi, Georgia
Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic LLC
Tbilisi, Georgia
Todua Clinic LLC
Tbilisi, Georgia
Semmelweis Egyetem Pulmonologiai Klinika
Budapest, Hungary
Országos Korányi Pulmonológiai Intézet
Budapest, Hungary
Orszagos Onkologiai Intezet
Budapest, Hungary
Debreceni Egyetem Klinikai Kozpont, Tudogyogyaszati Klinika
Debrecen, Hungary
Bács-Kiskun Megyei Oktatókórház, Onkoradiológiai Központ
Kecskemét, Hungary
Mátrai Gyógyintézet
Mátraháza, Hungary
Hetenyi Geza Korhaz, Onkologiai Kozpont
Szolnok, Hungary
Tüdőgyógyintézet Törökbálint, Onkológiai Osztályc
Törökbálint, Hungary
Centrum Onkologii im. prof. F. Lukaszczyka
Bydgoszcz, Poland
Krakowski Szpital Specjalistyczny im. Jana Pawla II Oddzial Onkologii z Pododdzialem Diagnostyki Nowotworow Klatki Piersiowej
Krakow, Poland
Centrum Terapii Współczesnej J. M. Jasnorzewska
Lodz, Poland
NeuroMed
Lublin, Poland
Med Polonia Sp z o.o.
Poznan, Poland
Centrum Medyczne Mrukmed
Rzeszów, Poland
Centrum Medyczne Pratia
Skorzewo, Poland
Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu, Oddzial Chemioterapii Nowotworow
Torun, Poland
NZOZ FORMED 2 Sp. z o.o.
Oświęcim, Oswiecim, Poland
Taipei Veterans General Hospital
Taipei, Beitou District, Taiwan
Chang-Gung Memorial Hospital - Linko
Taoyuan City, Guishan District, Taiwan
Tri-Service General Hospital
Taipei, Neihu District, Taiwan
Chang-Gung Memorial Hospital
Kaohsiung City, Niaosong District, Taiwan
Taipei Tzu Chi Hospital
New Taipei City, Xindian Dist, Taiwan
Taipei Medical University Hospital
Taipei, Xinyi District, Taiwan
National Taiwan University Hospital
Taipei, Zhongzheng District, Taiwan
Liv Hospital Ankara, Medikal Onkoloji Bilim Dalı
Ankara, Turkey (Türkiye)
İstinye Üniversitesi Hastanesi Liv Hospital Bahçeşehir
Istanbul, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.